SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Focused Visit (Follow-up) — Judy Garland

PatientJudy Garland
Date of birth1993-06-10
IdentifiersMRN HR-ML005-SYN; SSN (made up) 000-05-6127
Document date2026-08-31
AuthorMargaret Ellsworth-Diaz, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Ten-week review: phenobarbital taper, four weeks after stopping dextroamphetamine. [S]

History of Present Illness

Ms. Garland returns six weeks after her four-week review. She took the last dextroamphetamine tablet four weeks ago. For about two weeks afterwards she was tired, slept more and felt flat, and then her energy returned; she has had occasional urges to take a pill before rehearsals and has not acted on them. Her appetite has come back and she eats three meals on most days. She has gained 1.3 kg since the last visit, and she worries about it; we talked about it without a target. The step to 64.8 mg of phenobarbital went smoothly. Two weeks ago, at the sick visit for laryngitis, the next step was paused; her voice recovered within six days and she is back to singing. She sleeps about six hours on most nights. She saw the dietitian last week. Her mood is better. [S]

ElementDetail
DextroamphetamineStopped four weeks ago; two weeks of tiredness, then better
Phenobarbital64.8 mg a day for four weeks; step paused at the sick visit
LaryngitisResolved in six days
SleepAbout six hours; Insomnia Severity Index 13
MoodPHQ-9 9; GAD-7 8
Weight48.9 kg; three meals on most days

Review of Systems

SystemResultFinding
ConstitutionalNegativeEnergy back to her usual; no fever
Ears, nose, mouth, and throatNegativeVoice recovered; no sore throat
NeurologicalNegativeNo tremor or seizure-like episodes
PsychiatricPositiveOccasional urges to take a stimulant before rehearsals; mood better; no thoughts of suicide or self-harm

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Secobarbital 100 mg oral capsule, two capsules (200 mg) at bedtime; prescribed elsewhere for years; continued by this clinic at the verified dose, seven days at a time, until a supervised withdrawal is planned with addiction medicineTwo capsules at bedtime; no extra dosesOral route2026-06-22 to 2026-07-06completedS
Dextroamphetamine 10 mg oral tablet, one tablet each morning; no extra doses; prescribed elsewhere for weight and energyOne tablet each morningOral route2026-06-22 to 2026-07-20completedS
Dextroamphetamine 5 mg oral tablet, one tablet each morning for two weeks, then stopOne tablet each morning for two weeks, then stopOral route2026-07-20 to 2026-08-03completedS
Sertraline 25 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-06-22 to 2026-06-29completedS
Sertraline 50 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-06-29activeS
Phenobarbital 32.4 mg oral tablet, one tablet three times daily (97.2 mg a day), started in hospital in place of secobarbitalOne tablet three times dailyOral route2026-07-06 to 2026-07-20completedS
Phenobarbital 16.2 mg oral tablet on a written taper schedule in two or three divided doses: 81 mg a day from the four-week visit, lowered by 8.1 to 16.2 mg about every two weeks and paused when needed; dispensed two weeks at a timePer the written taper schedule, in two or three divided dosesOral route2026-07-20activeS
Medroxyprogesterone acetate 150 mg/mL injection, 150 mg into the muscle every 13 weeks150 mg intramuscularly every 13 weeksIntramuscular route2026-06-22activeS
Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for throat pain, no more than 3,000 mg a day, for up to five daysTwo tablets every 6 hours as needed, up to 3,000 mg a dayOral route2026-08-17 to 2026-08-22completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-08-31Body height151cmS
2026-08-31Body weight48.9kgS
2026-08-31Body mass index (BMI) [Ratio]21.4kg/m2S
2026-08-31Systolic blood pressure112mm[Hg]S
2026-08-31Diastolic blood pressure72mm[Hg]S
2026-08-31Heart rate72/minS
2026-08-31Respiratory rate14/minS
2026-08-31Body temperature36.7CelS
2026-08-31Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-08-31Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]9{score}S
2026-08-31Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]8{score}S

Physical Exam

Vital signs recorded on 2026-08-31; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 112/72, pulse 72; weight 48.9 kg, BMI 21.4
Ears, nose, mouth, and throatVoice clear; throat normal
NeurologicalNo tremor or nystagmus
PsychiatricBrighter; no signs of sedation or withdrawal

Problems

ProblemClinical statusVerificationCodeProvenance
Sedative, hypnotic, or anxiolytic use disorder (barbiturate), moderate, with physiological dependence; began with sleeping pills given in adolescence; synthetic modern episode linked to her documented lifelong dependence on prescribed sleeping pillsactiveconfirmed F13.20S — Synthetic modern coding. Tolerance and withdrawal are not counted toward the diagnosis for a medicine taken under medical supervision; five other criteria are met. Person-first language; not a claim about her real diagnosis.
Stimulant use disorder (prescribed amphetamine), mild; began with stimulants given in adolescence for weight and energy; synthetic modern episode linked to her documented pep pillsactiveconfirmed F15.10S — Synthetic modern coding; DSM-5-TR mild stimulant use disorder maps to F15.10. Tolerance and withdrawal are not counted for a supervised prescription.
Chronic insomnia disorder, long-standing, with sleep tied to sleeping pills since adolescenceactiveconfirmed G47.00S — Synthetic modern diagnosis anchored to the documented sleeping pills.
Contraception three months after childbirth while starting an enzyme-inducing drug: injectable progestin chosen because barbiturates, including any used for the withdrawal, weaken contraceptive pills, patches, rings and implantsactiveconfirmed Z30.013S — Synthetic contraception need; the birth is documented.
Major depressive disorder, single episode, moderate, with anxious distress; Mood Disorder Questionnaire negative and no history of mania or hypomaniaactiveconfirmed F32.1S — Synthetic modern diagnosis; not a claim about her real mood. The roster's bipolar disorder lead is not supported by the sources read and is not used.
Acute laryngitis, probably viral, during rehearsals, treated with voice rest and supportive care; resolvedresolvedconfirmed J04.0S — Synthetic acute illness; not a historical claim.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
Medication safetyBarbiturate dose, adherence, extra doses, and withdrawal signs (tremor, sweating, pulse, sleep, seizure warning signs)Every visitCompleted today64.8 mg a day; no withdrawal signs
Medication safetyTaper paceReductions of no more than about 20% every two weeks, slower toward the end; pause for symptoms, illness or a major performanceCompleted today81 to 64.8 mg two weeks after the first step; paused at the sick visit; 64.8 to 56.7 mg today (12.5%)
Medication safetyPrescription drug monitoring program checkBefore every controlled-substance prescriptionCompleted todayOnly this clinic's prescriptions; no opioid from the sick visit
LaboratoryUrine drug testing, explained as part of careAt the start, after the change to phenobarbital, and periodically during the taperUp to dateLast at the four-week visit; next at four months
Medication safetyLimited dispensing, locked storage and take-back of unused capsulesSeven days at first, then two weeks at a timeCompleted todayTwo-week supplies; locked box
Medication safetyMood, sleep, energy and appetite after stopping the stimulantWeekly for the first month after stopping, then each visitCompleted todayTwo weeks of tiredness and flat mood, then better; appetite back; occasional urges
ExaminationElectrocardiogramBefore continuing a stimulantNot indicatedStimulant stopped
SurveyCBT for insomnia, sleep diary and Insomnia Severity IndexWeekly CBT-I sessions; sleep diary and index at each visitCompleted todayWeekly sessions; Insomnia Severity Index 13
Medication safetyNew hypnotic (benzodiazepine, Z-drug, trazodone or antihistamine)Not recommended as a replacementNot indicatedNo new hypnotic
SurveyDepression (PHQ-9)At least monthly during acute treatmentDeferredPHQ-9 9 today, six weeks after the last score, longer than the monthly check advised; the sick visit did not repeat it. No harm resulted: her weekly therapist saw no worsening and today's score is lower. Corrective action: PHQ-9 at the preventive visit and monthly after that
SurveyAnxiety (GAD-7)With each PHQ-9 while anxiety is treatedCompleted todayGAD-7 8
Medication safetySertraline adherence and side effectsTwo weeks after starting or changing the dose, then each visitCompleted today50 mg daily; no side effects
SurveySuicide-risk review (C-SSRS screen since the last visit), safety plan, means safety and the 988 Suicide & Crisis LifelineEvery visitCompleted todayC-SSRS screen negative since the last visit; the 988 Suicide & Crisis Lifeline in her phone
ExaminationWeight, meals and disordered-eating screen, without a weight targetEvery visitCompleted todayWeight 48.9 kg, BMI 21.4; three meals on most days; discussed without a target
ReferralDietitian visitWithin a month of intakeCompleted todaySeen last week by the second dietitian; plan for meals around rehearsals
Medication safetyContraception that phenobarbital does not weakenMedroxyprogesterone every 13 weeksDueSecond injection due at the preventive visit in four weeks
Medication safetyNaloxoneReassess at every visit and whenever an opioid is prescribedNot indicatedNo opioids prescribed or used; codeine was avoided at the sick visit
Self-managementAlcohol and other sedativesEvery visitCompleted todayNo alcohol; no other sedatives or sleep aids

Goal progress:

Guideline basis: Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025); The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024); Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline (2017); Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians (2016); U.S. Medical Eligibility Criteria for Contraceptive Use, 2024 (2024); Prescription Drug Monitoring Programs (PDMPs) (2026); Depression and Suicide Risk in Adults: Screening (2023); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)

Follow-up: Nurse phone check before each taper step. Preventive visit in four weeks with the PHQ-9 and the second contraceptive injection. Four-month review in eight weeks with laboratory checks. Next scheduled visit 2026-09-28: periodic adult preventive visit. [S]